From: Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer
 | LMP-1 | LMP-2 | EBER 1 | EBER 2 | E2 | E6 | E7 |
---|---|---|---|---|---|---|---|
NF-κB | 0.6**** | 0.43*** | 0.33** | 0.31** | 0.37** | 0.64**** | 0.64**** |
TNF-α | 0.49** | 0.18 ns | 0.19 ns | 0.28* | 0.271** | 0.50*** | 0.504*** |
IL-1 | 0.501** | 0.42** | 0.34** | 0.22* | 0.40*** | 0.533*** | 0.529*** |
IL-6 | 0.66*** | 0.41** | 0.11 ns | 0.28* | 0.309** | 0.444*** | 0.435*** |
IL-8 | 0.54*** | 0.11 ns | 0.07ns | 0.08 ns | 0.393** | 0.603*** | 0.596*** |
IL-11 | 0.55*** | 0.3* | 0.34* | 0.136 ns | 0.341*** | 0.504*** | 0.509*** |
IL-17 | 0.56*** | 0.41** | 0.104 ns | 0.09 ns | 0.420*** | 0.726*** | 0.724*** |
VEGF | 0.57**** | 0.39* | 0.302* | 0.07 ns | 0.323** | 0.595*** | 0.604*** |
TGF-β | 0.51*** | 0.25* | 0.103 ns | −0.08 ns | 0.31** | 0.55*** | 0.59**** |
Rb | −0.47*** | 0.39** | 0.28** | 0.22* | −0.553*** | −0.751*** | −0.751*** |
P53 | −0.51*** | −0.401* | −0.201* | −0.05 ns | −0.456*** | −0.712*** | −0.715*** |
Survivin | 0.76**** | 0.39** | 0.308** | 0.17 ns | 0.528*** | 0.757*** | 0.761*** |
Bcl-2 | 0.49*** | 0.39** | 0.102 ns | −0.03 ns | 0.556*** | 0.743*** | 0.743*** |
ROS | 0.46** | 0.29* | 0.09 ns | 0.105 ns | 0.525*** | 0.763*** | 0.763*** |
RNS | 0.301* | 0.08 ns | 0.02 ns | 0.106 ns | 0.460*** | 0.654*** | 0.652*** |
CD44 | 0.8**** | 0.68**** | 0.48*** | 0.58**** | 0.21* | 0.34** | 0.29** |
TWIST | 0.53**** | 0.44*** | 0.44*** | 0.045 ns | 0/53** | 0/83**** | 0/86**** |
E-cad | −0.5*** | −0.2* | − 0.11* | − 0.096 ns | − 0/47** | − 0/71*** | −0/71*** |
N-cad | 0.51**** | 0.41** | 0.42** | 0.206 * | 0/51** | 0/85**** | 0/87**** |
PTPN13 | −0.409*** | − 0.15 ns | −0.15 ns | − 0.01 ns | − 0/48** | −0/41* | − 0/38* |
SLUG | 0.35* | 0.05 ns | 0.05 ns | 0.10 ns | 0/35* | 0/46** | 0/46** |